DLL3 CAR-T Therapy Targeting Brain Tumors
NCT07180927
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma of Cerebellum
Interventions
BIOLOGICAL:
4SCAR DLL3 T cells
Sponsor
Shenzhen Geno-Immune Medical Institute